These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 37407469)

  • 1. [Novel anti-complement therapeutics for hemolytic anemia].
    Nishimura JI
    Rinsho Ketsueki; 2023; 64(6):466-473. PubMed ID: 37407469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular pharmacology in complement-mediated hemolytic disorders.
    Bortolotti M; Barcellini W; Fattizzo B
    Eur J Haematol; 2023 Sep; 111(3):326-336. PubMed ID: 37308291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Novel therapeutic agents for hemolytic anemia].
    Nishimura JI
    Rinsho Ketsueki; 2023; 64(9):884-891. PubMed ID: 37793862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
    Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
    Front Immunol; 2019; 10():1157. PubMed ID: 31258525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy.
    Versino F; Fattizzo B
    Int J Lab Hematol; 2024 May; 46 Suppl 1():43-54. PubMed ID: 38622956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria.
    Xu B; Kang B; Chen J; Li S; Zhou J
    Blood Rev; 2024 Jul; 66():101210. PubMed ID: 38811284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegcetacoplan: First Approval.
    Hoy SM
    Drugs; 2021 Aug; 81(12):1423-1430. PubMed ID: 34342834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond.
    Gavriilaki E; de Latour RP; Risitano AM
    Blood; 2022 Jun; 139(25):3571-3582. PubMed ID: 34482398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current treatment of paroxysmal nocturnal hemoglobinuria and prospects for new therapeutic agents in the future].
    Nishimura JI
    Rinsho Ketsueki; 2021; 62(5):378-387. PubMed ID: 34108318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: Transfusion independence and abolition of extravascular hemolysis in a PNH patient treated with pegcetacoplan.
    Fattizzo B; Versino F; Zaninoni A; Marcello APML; Vercellati C; Artuso S; Barcellini W
    Front Immunol; 2022; 13():1060923. PubMed ID: 36532073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
    Risitano AM
    Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria.
    Heo YA
    Drugs; 2022 Dec; 82(18):1727-1735. PubMed ID: 36459381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs that inhibit complement.
    Schrezenmeier H; Höchsmann B
    Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.
    Wong R; Fishman J; Wilson K; Yeh M; Al-Adhami M; Zion A; Yee CW; Huynh L; Duh MS
    Adv Ther; 2023 Apr; 40(4):1571-1589. PubMed ID: 36750531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosing Patterns of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab in the United States: A Retrospective Claims-Based Analysis.
    Cheng WY; Fishman J; Yenikomshian M; Mahendran M; Kunzweiler C; Vu JD; Duh MS
    Adv Ther; 2024 Jan; 41(1):413-430. PubMed ID: 37999832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria.
    Frieri C; Peffault de Latour R; Sicre De Fontbrune F
    Expert Opin Emerg Drugs; 2022 Mar; 27(1):33-43. PubMed ID: 35078384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
    Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resolution of extravascular hemolysis with oral iptacopan monotherapy in a patient with treatment experienced paroxysmal nocturnal hemoglobinuria (PNH).
    Füreder W; Thalhammer R; Valent P
    Wien Klin Wochenschr; 2024 Aug; 136(15-16):472-475. PubMed ID: 38954058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Ariceta G
    Expert Rev Clin Pharmacol; 2023 May; 16(5):401-410. PubMed ID: 37128905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
    Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
    Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.